Martingale Asset Management L P Acquires 6,965 Shares of Viemed Healthcare, Inc. (NASDAQ:VMD)

Martingale Asset Management L P boosted its holdings in shares of Viemed Healthcare, Inc. (NASDAQ:VMD) by 28.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,385 shares of the company’s stock after purchasing an additional 6,965 shares during the quarter. Martingale Asset Management L P’s holdings in Viemed Healthcare were worth $230,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in VMD. Vanguard Group Inc. lifted its position in shares of Viemed Healthcare by 53.0% in the 1st quarter. Vanguard Group Inc. now owns 1,781,914 shares of the company’s stock worth $16,803,000 after acquiring an additional 617,009 shares during the period. Apis Capital Advisors LLC lifted its position in shares of Viemed Healthcare by 193.0% in the 2nd quarter. Apis Capital Advisors LLC now owns 234,400 shares of the company’s stock worth $1,535,000 after acquiring an additional 154,400 shares during the period. Victory Capital Management Inc. lifted its position in shares of Viemed Healthcare by 748.2% in the 3rd quarter. Victory Capital Management Inc. now owns 108,497 shares of the company’s stock worth $795,000 after acquiring an additional 95,706 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in shares of Viemed Healthcare in the 1st quarter worth approximately $97,000. Finally, GSA Capital Partners LLP raised its holdings in shares of Viemed Healthcare by 37.1% in the 3rd quarter. GSA Capital Partners LLP now owns 17,836 shares of the company’s stock worth $131,000 after buying an additional 4,829 shares in the last quarter. Institutional investors own 74.24% of the company’s stock.

Insider Transactions at Viemed Healthcare

In related news, Director Nitin Kaushal sold 5,995 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $8.58, for a total transaction of $51,437.10. Following the completion of the sale, the director now directly owns 126,843 shares of the company’s stock, valued at $1,088,312.94. This trade represents a 4.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Randy E. Dobbs sold 36,261 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $9.28, for a total value of $336,502.08. Following the sale, the director now directly owns 107,706 shares of the company’s stock, valued at $999,511.68. This represents a 25.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,256 shares of company stock valued at $674,739. Corporate insiders own 20.00% of the company’s stock.

Viemed Healthcare Trading Up 0.2 %

Shares of VMD opened at $8.72 on Thursday. Viemed Healthcare, Inc. has a 1 year low of $6.21 and a 1 year high of $10.44. The company has a current ratio of 1.31, a quick ratio of 1.19 and a debt-to-equity ratio of 0.03. The stock has a 50 day simple moving average of $8.70 and a 200-day simple moving average of $7.65. The stock has a market cap of $339.56 million, a PE ratio of 32.30 and a beta of 1.46.

Viemed Healthcare (NASDAQ:VMD) last issued its earnings results on Wednesday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. Viemed Healthcare had a return on equity of 8.72% and a net margin of 4.87%. The business had revenue of $58.00 million during the quarter.

Viemed Healthcare Profile

Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.